Professional Summary »
Specializing In »
Practice Locations »
Patient Ratings »
Referring Physicians »
Specializing In
- Addiction Medicine
- Sports Medicine
- Stress Management and Anxiety
Biography
I am a family doctor and physician scientist interested in translational research to improve preventive health and public health strategies to improve population health. My research focuses on the integration of clinical and translational research into nicotine dependence using genomic and neuromaging investigations to identify and validate biomarkers for smoking cessation, to reduce health disparities in cardiovascular disease and cancer, and to employ community engagement and clinical implementation science approaches to fill critical gaps in preventive medicine. Recent work includes the identification of a genome-wide significant genetic marker for smoking intensity in African Americans that is associated with pharmacogenetic treatment response for smoking cessation and risk of lung cancer in African Americans. I am also an investigator in the GWAS and Sequencing Consortium of Alcohol and Nicotine Use (GSCAN) and the NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium and the Stanford Precision Health for Ethnic and Racial Equity (SPHERE) Transdisciplinary Collaborative Center. Current and future research is translating evidence in systematic reviews and meta-analyses to evidence-based guidelines, investigations of publication bias and proposed reforms to improve the fidelity of research through open science, clinical implementation sciences for precision health, and training the primary care workforce in core competencies of genetic medicine to enable precision health for all. Born and raised in Seattle, I love the west and Pac-12 football, fishing, sailing, marathon running and rowing.
View Full Biography »
Professional Summary
Education & Certifications
- BS, University of Washington, Zoology (1990)
- Medical Education: University of Washington School of Medicine (1995) WA
- Internship: NH Dartmouth Family Practice Residency (1996) NH
- Residency: NH Dartmouth Family Practice Residency (1998) NH
- Board Certification: Family Medicine, American Board of Family Medicine (1998)
- SM, Harvard School of Public Health, Health & Social Behavior (1999)
- Fellowship, Cancer Research UK GPRG, University of Oxford, Pharmacogenetics (2002)
- Fellowship, C. Everett Koop Institute at Dartmouth, Tobacco Control (2002)
- Fellowship, American Academy of Family Physicians, Advanced Research Training (2003)
- Board Recertification, Family Medicine, American Board of Family Medicine (2005)
- Fellowship, Robert Wood Johnson Foundation Generalist Physician Faculty Scholar, Pharmacogenetics of Smoking Cessation in Primary Care (2006)
- Professional Education: University of Oxford (2006) UK
- Fellowship, NIDA K08 Mentored Clinical Scientist, Nicotine Dependence (2007)
- Fellowship, National Academies of Sciences, Engineering, and Medicine, Health Policy (James C. Puffer, M.D./American Board of Family Medicine/National Academy of Medicine Anniversary Fellow) (2013)
- Board Recertification, Family Medicine, American Board of Family Medicine (2015)
Honors & Awards
- Advanced Research Training Award, American Academy of Family Physicians (2001-2003)
- Benjamin Meaker Visiting Professorship, University of Bristol (2010)
- Board of US BMJ Fellows, BMJ Group (2013)
- Dean's Teaching Excellence Award, Brown Alpert Medical School (2001)
- Family Practice Scholar Award, Glaxo-Wellcome (1997)
- Fellow, American Academy of Family Physicians, American Academy of Family Physicians (2017)
- Generalist Physician Faculty Scholars Award, Robert Wood Johnson Foundation (2002-2006)
- James C. Puffer, M.D./ABFM/National Academy of Medicine Anniversary Fellow, National Academies of Science, Engineering, and Medicine (2011-2013)
- K08 Mentored Clinical Scientist Development Award, National Institute on Drug Abuse/National Institutes of Health (2002-2008)
- MCR President, Green College, University of Oxford (2004-2005)
- Profiles in Competence Teaching Award, Brown Alpert Medical School (2002)
Administrative Appointments
- Adjunct Associate Professor of Family Medicine, Brown Alpert Medical School (2009 - 2014)
- Assistant Professor of Family Medicine, Brown Alpert Medical School (2001 - 2009)
- Associate Professor of Medicine, Stanford University School of Medicine (2014 - Present)
- Clinical Associate Professor (secondary appointment), Stanford Prevention Research Center (2011 - Present)
- Clinical Associate Professor of Family & Community Medicine, Stanford University School of Medicine (2009 - 2014)
- Director of C. Everett Koop Health Policy Fellowship, Brown Alpert Medical School (2003 - 2009)
- Director of Primary Care Genetics Laboratory & Translational Research Center, Memorial Hospital of Rhode Island/Brown Alpert Medical School (2002 - 2009)
- Instructor of Family Medicine, Brown Alpert Medical School (1999 - 2001)
- Member, Stanford Cancer Institute (2016 - Present)
- Member Affiliate, Meta-Research Innovation Center at Stanford (METRICS) (2014 - Present)
- Physician curator, PharmGKB (2010 - 2011)
Publications
-
Reflections from a rotation in Cambridge, England
David, S. P. (2000). Reflections from a rotation in Cambridge, England. FAMILY MEDICINE, 32(5), 310–312. -
A civic role for physicians in the promotion of global tobacco control
David, S. P. (2001). A civic role for physicians in the promotion of global tobacco control. FAMILY PRACTICE, 18(1), 107–107. -
Social marketing: Application to medical education
David, S. P., & Greer, D. S. (2001). Social marketing: Application to medical education. ANNALS OF INTERNAL MEDICINE, 134(2), 125–127. -
Media advocacy for the office-based teacher of family medicine
David, S. P. (2001). Media advocacy for the office-based teacher of family medicine. FAMILY MEDICINE, 33(1), 16–18. -
Should we recommend nicotine replacement therapy?
David, S. P. (2001). Should we recommend nicotine replacement therapy? AMERICAN FAMILY PHYSICIAN, 63(11), 2245–2247. -
Opioid antagonists for smoking cessation.
David, S., Lancaster, T., & Stead, L. F. (2001). Opioid antagonists for smoking cessation. Cochrane Database of Systematic Reviews , (3), CD003086-? -
International tobacco control: A focus group study of US anti-tobacco activists
David, S., DeJong, W., & Resnick, N. (2001). International tobacco control: A focus group study of US anti-tobacco activists. JOURNAL OF PUBLIC HEALTH POLICY, 22(4), 415–428. -
No association between functional catechol O-methyl transferase 1947A > G polymorphism and smoking initiation, persistent smoking or smoking cessation
David, S. P., Johnstone, E., Griffiths, S. E., Murphy, M., Yudkin, P., Mant, D., & Walton, R. (2002). No association between functional catechol O-methyl transferase 1947A > G polymorphism and smoking initiation, persistent smoking or smoking cessation. PHARMACOGENETICS, 12(3), 265–268. -
Should we use multiple risk factor interventions for the primary prevention of coronary heart disease?
David, S. P. (2002). Should we use multiple risk factor interventions for the primary prevention of coronary heart disease? AMERICAN FAMILY PHYSICIAN, 66(2), 245–246. -
Should we prescribe antibiotics for acute conjunctivitis?
David, S. P. (2002). Should we prescribe antibiotics for acute conjunctivitis? American Family Physician, 66(9), 1649–1650. -
Are family physicians willing to use pharmacogenetics for smoking cessation therapy?
Stamp, M. J., & David, S. P. (2003). Are family physicians willing to use pharmacogenetics for smoking cessation therapy? FAMILY MEDICINE, 35(2), 83–83. -
Comment on "The public health implications of smoking-induced decreased serum and red blood cell folate levels"
David, S. P., & Eaton, C. B. (2003). Comment on "The public health implications of smoking-induced decreased serum and red blood cell folate levels". NICOTINE & TOBACCO RESEARCH, 5(3), 397–399. -
Genetic susceptibility to breast cancer: Teaching points
Gramling, R., & David, S. (2003). Genetic susceptibility to breast cancer: Teaching points. FAMILY MEDICINE, 35(7), 466–468. -
Should we offer routine breast cancer screening with mammography?
David, S. P. (2003). Should we offer routine breast cancer screening with mammography? AMERICAN FAMILY PHYSICIAN, 68(2), 260–262. -
Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?
David, S. P., Niaura, R., Papandonatos, G. D., Shadel, W. G., Burkholder, G. J., Britt, D. M., … Walton, R. T. (2003). Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? NICOTINE & TOBACCO RESEARCH, 5(6), 935–942. -
Pharmacogenetics
David, S. P. (2004). Pharmacogenetics. PRIMARY CARE, 31(3), 543-? -
Does providing hereditary breast cancer risk assessment support to practicing physicians decrease the likelihood of them discussing such risk with their patients?
Gramling, R., Duffy, C., & David, S. (2004). Does providing hereditary breast cancer risk assessment support to practicing physicians decrease the likelihood of them discussing such risk with their patients? GENETICS IN MEDICINE, 6(6), 542–542. -
Envisaging and applying a unifying three-dimensional theoretical framework for generalist physicians.
David, S. P., Eaton, C. B., Taylor, J. S., Stamp, M. J., Cyr, M., Siegel, B., … Walton, R. (2004). Envisaging and applying a unifying three-dimensional theoretical framework for generalist physicians. Medicine and Health, Rhode Island, 87(11), 336–340. -
Are there sex differences in transdermal nicotine replacement therapy patch efficacy? A meta-analysis
Munafo, M., Bradburn, M., Bowes, L., & David, S. (2004). Are there sex differences in transdermal nicotine replacement therapy patch efficacy? A meta-analysis. NICOTINE & TOBACCO RESEARCH, 6(5), 769–776. -
A functional genetic variation of the serotonin (5-HT) transporter affects 5-HT1A receptor binding in humans
David, S. P., Murthy, N. V., Rabiner, E. A., Munafo, M. R., Johnstone, E. C., Jacob, R., … Grasby, P. M. (2005). A functional genetic variation of the serotonin (5-HT) transporter affects 5-HT1A receptor binding in humans. JOURNAL OF NEUROSCIENCE, 25(10), 2586–2590. -
Ventral striatum/nucleus accumbens activation to smoking-related pictorial cues in smokers and nonsmokers: A functional magnetic resonance imaging study
David, S. P., Munafo, M. R., Johansen-Berg, H., Smith, S. M., Rogers, R. D., Matthews, P. M., & Walton, R. T. (2005). Ventral striatum/nucleus accumbens activation to smoking-related pictorial cues in smokers and nonsmokers: A functional magnetic resonance imaging study. BIOLOGICAL PSYCHIATRY, 58(6), 488–494. -
Fellowship training in family medicine at Brown: adding depth to breadth.
Long, R., David, S. P., Monroe, A., & Shaw, J. (2006). Fellowship training in family medicine at Brown: adding depth to breadth. Medicine and Health, Rhode Island, 89(8), 274–275. -
Building a successful research enterprise in family medicine: the Brown experience.
David, S. P., Eaton, C. B., Culpepper, L., Goldman, R. E., Lavallee, L. K., & Simmons, E. M. (2006). Building a successful research enterprise in family medicine: the Brown experience. Medicine and Health, Rhode Island, 89(8), 281–284. -
Opioid antagonists for smoking cessation
David, S., Lancaster, T., Stead, L. F., & Evins, A. E. (2006). Opioid antagonists for smoking cessation. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (4). -
The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: Follow-up of a randomized controlled trial
David, S. P., Munafo, M. R., Murphy, M. F. G., Walton, R. T., & Johnstone, E. C. (2007). The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: Follow-up of a randomized controlled trial. NICOTINE & TOBACCO RESEARCH, 9(2), 225–231. -
Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch
David, S. P., Munafo, M. R., Murphy, M. F. G., Proctor, M., Walton, R. T., & Johnstone, E. C. (2008). Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch. PHARMACOGENOMICS JOURNAL, 8(2), 122–128. -
Association of COMT Val(108/158) met genotype with smoking cessation in a nicotine replacement therapy randomized trial
Johnstone, E. C., Elliot, K. M., David, S. P., Murphy, M. F. G., Walton, R. T., & Munafo, M. R. (2007). Association of COMT Val(108/158) met genotype with smoking cessation in a nicotine replacement therapy randomized trial. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 16(6), 1065–1069. -
Successful Latino community partnership program for smoking cessation
David, S. P., Smith, M., Lee, C. S., & Sullivan, G. (2007). Successful Latino community partnership program for smoking cessation. AMERICAN JOURNAL OF PUBLIC HEALTH, 97(8), 1348–1349. -
Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation
David, S. P., Brown, R. A., Papandonatos, G. D., Kahler, C. W., Lloyd-Richardson, E. E., Munafo, M. R., … Niaura, R. (2007). Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. NICOTINE & TOBACCO RESEARCH, 9(8), 821–833. -
Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: Analysis of pooled data from two clinical trials
David, S. P., Strong, D. R., Munafo, M. R., Brown, R. A., Lloyd-Richardson, E. E., Wileyto, P. E., … Niaura, R. (2007). Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: Analysis of pooled data from two clinical trials. NICOTINE & TOBACCO RESEARCH, 9(12), 1251–1257. -
Chronic cigarette smoking and the microstructural integrity of white matter in healthy adults: A diffusion tensor imaging study
Paul, R. H., Grieve, S. M., Niaura, R., David, S. P., Laidlaw, D. H., Cohen, R., … Gordon, E. (2008). Chronic cigarette smoking and the microstructural integrity of white matter in healthy adults: A diffusion tensor imaging study. NICOTINE & TOBACCO RESEARCH, 10(1), 137–147. -
A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation
Welton, N. J., Johnstone, E. C., David, S. P., & Munafo, M. R. (2008). A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation. NICOTINE & TOBACCO RESEARCH, 10(1), 231–240. -
Smoking cessation.
Koplan, K. E., David, S. P., & Rigotti, N. A. (2008). Smoking cessation. BMJ (Clinical Research Ed.), 336(7637), 217-? -
Smoking cessation in primary care
David, S. P., & Munafo, M. R. (2008). Smoking cessation in primary care. BRITISH MEDICAL JOURNAL, 336(7655), 1200–1201. -
-
Molecular genetics of successful smoking cessation - Convergent genome-wide association study results
Uhl, G. R., Liu, Q.-R., Drgon, T., Johnson, C., Walther, D., David, S. P., … Rose, E. (2008). Molecular genetics of successful smoking cessation - Convergent genome-wide association study results. ARCHIVES OF GENERAL PSYCHIATRY, 65(6), 683–693. -
-
-
[Smoking cessation].
Koplan, K. E., David, S. P., & Rigotti, N. A. (2008). [Smoking cessation]. Praxis, 97(22), 1185–1186. -
Association of the DRD2 gene Taq1A polymorphism and smoking behavior: A meta-analysis and new data
Munafo, M. R., Timpson, N. J., David, S. P., Ebrahim, S., & Lawlor, D. A. (2009). Association of the DRD2 gene Taq1A polymorphism and smoking behavior: A meta-analysis and new data. NICOTINE & TOBACCO RESEARCH, 11(1), 64–76. -
-
Genome-wide association for smoking cessation success: participants in the Patch in Practice trial of nicotine replacement
Uhl, G. R., Drgon, T., Johnson, C., Walther, D., Aveyard, P., Murphy, M., … Munafo, M. R. (2010). Genome-wide association for smoking cessation success: participants in the Patch in Practice trial of nicotine replacement. PHARMACOGENOMICS, 11(3), 357–367. -
Effects of nicotine withdrawal on verbal working memory and associated brain response
Sweet, L. H., Mulligan, R. C., Finnerty, C. E., Jerskey, B. A., David, S. P., Cohen, R. A., & Niaura, R. S. (2010). Effects of nicotine withdrawal on verbal working memory and associated brain response. PSYCHIATRY RESEARCH-NEUROIMAGING, 183(1), 69–74. -
-
-
-
Association between CHRNA5 genetic variation at rs16969968 and brain reactivity to smoking images in nicotine dependent women
Janes, A. C., Smoller, J. W., David, S. P., Frederick, B. deB., Haddad, S., Basu, A., … Kaufman, M. J. (2012). Association between CHRNA5 genetic variation at rs16969968 and brain reactivity to smoking images in nicotine dependent women. DRUG AND ALCOHOL DEPENDENCE, 120(1-3), 7–13. -
-
Interaction between heavy smoking and CYP2A6 genotypes on type 2 diabetes and its possible pathways
Liu, T., Chen, W.-Q., David, S. P., Tyndale, R. F., Wang, H., Chen, Y.-ming, … Ling, W.-H. (2011). Interaction between heavy smoking and CYP2A6 genotypes on type 2 diabetes and its possible pathways. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 165(6), 961–67. -
-
Chronic psychosocial stressors and salivary biomarkers in emerging adults
Bergen, A. W., Mallick, A., Nishita, D., Wei, X., Michel, M., Wacholder, A., … Andrews, J. A. (2012). Chronic psychosocial stressors and salivary biomarkers in emerging adults. PSYCHONEUROENDOCRINOLOGY, 37(8), 1158–1170. -
Association between daily cigarette consumption and hypertension moderated by CYP2A6 genotypes in Chinese male current smokers
Liu, T., Tyndale, R. F., David, S. P., Wang, H., Yu, X.-Q., Chen, W., … Chen, W.-Q. (2013). Association between daily cigarette consumption and hypertension moderated by CYP2A6 genotypes in Chinese male current smokers. JOURNAL OF HUMAN HYPERTENSION, 27(1), 24–30. -
-
PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6
McDonagh, E. M., Wassenaar, C., David, S. P., Tyndale, R. F., Altman, R. B., Whirl-Carrillo, M., & Klein, T. E. (2012). PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. PHARMACOGENETICS AND GENOMICS, 22(9), 695–708. -
-
-
Genome-wide meta-analyses of smoking behaviors in African Americans
David, S. P., Hamidovic, A., Chen, G. K., Bergen, A. W., Wessel, J., Kasberger, J. L., … Furberg, H. (2012). Genome-wide meta-analyses of smoking behaviors in African Americans. TRANSLATIONAL PSYCHIATRY, 2. -
Pharmacogenetic Smoking Cessation Intervention in a Health Care Setting: A Pilot Feasibility Study
McClure, J. B., Swan, G. E., St John, J., Fauver, R., Javitz, H. S., Bergen, A. W., … David, S. P. (2013). Pharmacogenetic Smoking Cessation Intervention in a Health Care Setting: A Pilot Feasibility Study. NICOTINE & TOBACCO RESEARCH, 15(2), 518–26. -
Improving America's health requires community-level solutions: Folsom revisited.
Improving America's health requires community-level solutions: Folsom revisited. (2012). American Family Physician, 86(4), 1–2. -
-
-
Opioid antagonists for smoking cessation
David, S. P., Lancaster, T., Stead, L. F., Evins, A. E., & Prochaska, J. J. (2013). Opioid antagonists for smoking cessation. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (6). -
The Transatlantic Conference on Tobacco (TACT): a model for international tobacco policy activism.
David, S. P. (1998). The Transatlantic Conference on Tobacco (TACT): a model for international tobacco policy activism. Journal of Cancer Education , 13(4), 253–254. -
Evaluation of an educational intervention for medical students to promote competency in social and community determinants of health.
Evaluation of an educational intervention for medical students to promote competency in social and community determinants of health. (2004). ABSAME, 10(2). -
Dopamine Transporters: Chemistry, Biology, and Pharmacology.
Dopamine Transporters: Chemistry, Biology, and Pharmacology. (2009). Clin Pharmacol Ther., 85(1). -
Lifestyle Medicine by Gary Egger, Andrew Binns, and Stephen Rossner.
David, S. P. (2009). Lifestyle Medicine by Gary Egger, Andrew Binns, and Stephen Rossner. Am J Lifestyle Med., 3(5). -
Smoking cessation for the primary care physician.
Smoking cessation for the primary care physician. (2001). Prim Care Rep., 7(24). -
Investigating subgroups in smoking cessation treatment response: Response to Perkins.
Investigating subgroups in smoking cessation treatment response: Response to Perkins. (2004). Nicotine Tob Res, 6(5). -
The Pharmacogenetics of Nicotine Addiction and Smoking Cessation.
The Pharmacogenetics of Nicotine Addiction and Smoking Cessation. (2006). Chapter 21 in: Pharmacogenomics and Proteomics: Enabling the Practice of Personalized Medicine. Edited by Wong SHY, Linder MW, Valdes, Jr. R. AACC Press, Washington, DC., 1. -
-
Studies of Genetic Influences on Nicotine Dependence Utilising Functional Neuroimaging.
Studies of Genetic Influences on Nicotine Dependence Utilising Functional Neuroimaging. (2006). Doctoral Thesis: University of Oxford, Bodleian Library, Oxford, UK. -
Investigating subgroups in smoking cessation treatment response: Response to Perkins
Munafo, M. R., Bradburn, M., Bowes, L., & David, S. (2004). Investigating subgroups in smoking cessation treatment response: Response to Perkins. NICOTINE & TOBACCO RESEARCH, 6(5), 865–867. -
Effects of Acute Nicotine Abstinence on Cue-elicited Ventral Striatum/Nucleus Accumbens Activation in Female Cigarette Smokers: A Functional Magnetic Resonance Imaging Study
David, S. P., Munafo, M. R., Johansen-Berg, H., MacKillop, J., Sweet, L. H., Cohen, R. A., … Walton, R. T. (2007). Effects of Acute Nicotine Abstinence on Cue-elicited Ventral Striatum/Nucleus Accumbens Activation in Female Cigarette Smokers: A Functional Magnetic Resonance Imaging Study. BRAIN IMAGING AND BEHAVIOR, 1(3-4), 43–57. -
-
CHRONIC STRESS & SALIVARY BIOMARKERS
Mallick, A., Bergen, A., Nishita, D., Wei, X., Michel, M., David, S. P., … Andrews, J. (2013). CHRONIC STRESS & SALIVARY BIOMARKERS. JOURNAL OF INVESTIGATIVE MEDICINE, 61(1), 141–141. -
Communities of Solution: Partnerships for Population Health
Griswold, K. S., Lesko, S. E., & Westfall, J. M. (2013). Communities of Solution: Partnerships for Population Health. JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 26(3), 232–238. -
No association between germline variation in catechol-O-methyltransferase and colorectal cancer survival in postmenopausal women
Passarelli, M. N., Newcomb, P. A., Makar, K. W., Burnett-Hartman, A. N., Phipps, A. I., David, S. P., … Peters, U. (2014). No association between germline variation in catechol-O-methyltransferase and colorectal cancer survival in postmenopausal women. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 21(4), 415–420. -
-
-
Evidence of reporting biases in voxel-based morphometry (VBM) studies of psychiatric and neurological disorders.
Fusar-Poli, P., Joaquim, R., Marianna, F., Andrea, M., Stefan, B., Fabio, D. F., … David, S. P. (2013). Evidence of reporting biases in voxel-based morphometry (VBM) studies of psychiatric and neurological disorders. Human Brain Mapping. -
Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion.
David, S. P., Strong, D. R., Leventhal, A. M., Lancaster, M. A., McGeary, J. E., Munafò, M. R., … Niaura, R. (2013). Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. Addiction , 108(12), 2202–2211. -
-
Clinical interpretation and implications of whole-genome sequencing.
Dewey, F. E., Grove, M. E., Pan, C., Goldstein, B. A., Bernstein, J. A., Chaib, H., … Quertermous, T. (2014). Clinical interpretation and implications of whole-genome sequencing. JAMA, 311(10), 1035–45. -
Teaching tobacco dependence treatment and counseling skills during medical school: Rationale and design of the Medical Students helping patients Quit tobacco (MSQuit) group randomized controlled trial.
Hayes, R. B., Geller, A., Churchill, L., Jolicoeur, D., Murray, D. M., Shoben, A., … Ockene, J. K. (2014). Teaching tobacco dependence treatment and counseling skills during medical school: Rationale and design of the Medical Students helping patients Quit tobacco (MSQuit) group randomized controlled trial. Contemporary Clinical Trials, 37(2), 284–293. -
Commentary on Chen et al. (2014): Another step on the road to clinical utility of pharmacogenetics for smoking cessation?
David, S. P. (2014). Commentary on Chen et al. (2014): Another step on the road to clinical utility of pharmacogenetics for smoking cessation? ADDICTION, 109(1), 138–139. -
Systematic review and meta-analysis of opioid antagonists for smoking cessation.
David, S. P., Chu, I. M., Lancaster, T., Stead, L. F., Evins, A. E., & Prochaska, J. J. (2014). Systematic review and meta-analysis of opioid antagonists for smoking cessation. BMJ Open, 4(3). -
-
-
-
Smoking behavior and association of melanoma and nonmelanoma skin cancer in the Women's Health Initiative.
Henderson, M. T., Kubo, J. T., Desai, M., David, S. P., Tindle, H., Sinha, A. A., … Tang, J. Y. (2015). Smoking behavior and association of melanoma and nonmelanoma skin cancer in the Women's Health Initiative. Journal of the American Academy of Dermatology, 72(1), 190–191.e3. -
Differential Efficacy of Nicotine Replacement Among Overweight and Obese Women Smokers.
Strong, D. R., David, S. P., Johnstone, E. C., Aveyard, P., Murphy, M. F., & Munafò, M. R. (2015). Differential Efficacy of Nicotine Replacement Among Overweight and Obese Women Smokers. Nicotine & Tobacco Research , 17(7), 855–861. -
-
Smoking behavior and association of melanoma and nonmelanoma skin cancer in the Women's Health Initiative
Henderson, M. T., Kubo, J. T., Desai, M., David, S. P., Tindle, H., Sinha, A. A., … Tang, J. Y. (2015). Smoking behavior and association of melanoma and nonmelanoma skin cancer in the Women's Health Initiative. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 72(1), 190–191. -
Making Personalized Health Care Even More Personalized: Insights From Activities of the IOM Genomics Roundtable.
David, S. P., Johnson, S. G., Berger, A. C., Feero, W. G., Terry, S. F., Green, L. A., … Ginsburg, G. S. (2015). Making Personalized Health Care Even More Personalized: Insights From Activities of the IOM Genomics Roundtable. Annals of Family Medicine, 13(4), 373–80. -
-
-
-
-
-
Retrospective analysis of changing characteristics of treatment-seeking smokers: implications for further reducing smoking prevalence.
Leyro, T. M., Crew, E. E., Bryson, S. W., Lembke, A., Bailey, S. R., Prochaska, J. J., … David, S. P. (2016). Retrospective analysis of changing characteristics of treatment-seeking smokers: implications for further reducing smoking prevalence. BMJ Open, 6(6). -
-
-
-
The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings.
Saccone, N. L., Baurley, J. W., Bergen, A. W., David, S. P., Elliott, H. R., Foreman, M. G., … Chen, L.-S. (2017). The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings. Nicotine & Tobacco Research . -
Leveraging genomic data in smoking cessation trials in the era of Precision Medicine: Why and how.
Chen, L.-S., Zawertailo, L., Piasecki, T. M., Kaprio, J., Foreman, M., Elliott, H. R., … Saccone, N. L. (2017). Leveraging genomic data in smoking cessation trials in the era of Precision Medicine: Why and how. Nicotine & Tobacco Research . -
Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers.
Schuit, E., Panagiotou, O. A., Munafò, M. R., Bennett, D. A., Bergen, A. W., & David, S. P. (2017). Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. The Cochrane Database of Systematic Reviews, 9, CD011823. -
An Evidence Framework for Genetic Testing
Berg, A. O. (2017). An Evidence Framework for Genetic Testing. National Academies Press. -
Genomic and Precision Medicine, 3rd Edition, Primary Care
David, S. P. (2017). Genomic and Precision Medicine, 3rd Edition, Primary Care. (S. P. David, Ed.). Elsevier. -
-
Patient and provider perspectives on the development of personalized medicine: a mixed-methods approach.
Puryear, L., Downs, N., Nevedal, A., Lewis, E. T., Ormond, K. E., Bregendahl, M., … Palaniappan, L. (2017). Patient and provider perspectives on the development of personalized medicine: a mixed-methods approach. Journal of Community Genetics. -
-
-
-
-
Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries.
Zekavat, S. M., Ruotsalainen, S., Handsaker, R. E., Alver, M., Bloom, J., Poterba, T., … Natarajan, P. (2018). Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries. Nature Communications, 9(1), 2606. -
Deep-coverage whole genome sequences and blood lipids among 16,324 individuals.
Natarajan, P., Peloso, G. M., Zekavat, S. M., Montasser, M., Ganna, A., Chaffin, M., … Kathiresan, S. (2018). Deep-coverage whole genome sequences and blood lipids among 16,324 individuals. Nature Communications, 9(1), 3391. -
Tobacco Use Disorder
MacKillop, J., Gray, J. C., Owen, M. M., Laude, J., & David, S. (2017). Tobacco Use Disorder. (J. MacKillop, G. Kenna, L. Leggio, & L. A. Ray, Eds.), Integrating Psychological and Pharmacological Treatments for Addictive Disorders: An Evidence-Based Guide. Routledge. -
-
-
-
-
Meta-analysis of up to 622,409 individuals identifies 40 novel smoking behaviour associated genetic loci.
Erzurumluoglu, A. M., Liu, M., Jackson, V. E., Barnes, D. R., Datta, G., Melbourne, C. A., … Howson, J. M. (2019). Meta-analysis of up to 622,409 individuals identifies 40 novel smoking behaviour associated genetic loci. Molecular Psychiatry. -
-
-
Practice Locations
211 Quarry Rd Ste 102 Palo Alto, CA
Palo Alto, CAPatient Reviews
(23 reviews)
Dr. David was amazing. He was so helpful and had a wonderful bedside manner. I feel so fortunate to have been able to see him, especially on such short notice!
Dr. took time to read chart before coming in. Explained his thoughts and suggested follow up. Perfect doctor
I was very impressed with Dr. David.
good
Dr. David was outstanding! I told many of my family and friends about how grateful I am for him. I had previously met with another doctor (not associated with Stanford) for the same condition, and that doctor seemed to have almost no knowledge about the condition and therefore dismissed it as not having could have happened and would not help me at all. Dr. David was very knowledgeable and said that my symptoms are exactly the body's response to the event that occurred and make complete sense. He was very helpful in explaining the condition and referring me to a specialist. He was also very kind and compassionate and explained the pros and cons of various options, letting me know what he thought would be best for my health, but ultimately letting me make the decision. Many thanks to Dr. David!
Dr. Shaun David was outstanding. I wish he could be my family physician.
Strong empathetic respectful intelligence.
After we had completed our discussion regarding the immediate medical concern, Dr. David took the time to ask me how I was holding up under the stress of metastatic colon cancer. His genuine concern was much appreciated!
The physician was really wonderful! He took the time to try and figure out what was wrong.
One of the best - never forget this event - So much CARE.
Good experience.
The visit was perfect! I was using wrong OTC meds in the wrong order. He shaped it for me.
The Dr. was very kind and professional. He answered all my questions.
Outstanding physician. Actually called me the next morning to check up on me and explain my lab tests. I was very impressed with his care.
Dr was friendly, but didn't ask many questions, with the result that I wasn't even sure if he knew I'd been in a very bad car accident as opposed to a fender bender. I was surprised he didn't ask more questions to try to assess what was going on.
Excellent! FAR above my expectations!! But do the same doctors always work at the express facility, or are the doctors maybe on some kind of revolving schedule with other doctors from various other areas?
Dr. David was outstanding.
I really appreciated that Dr. David ordered the tests I needed. It made me feel a lot better. He listened well and took my post medical conditions into account and followed up weeks later.
very professional
The doctor was friendly, comforting and all around excellent!
Extremely courteous, thoughtful.
Fantastic care!
Every one is so great. They care totally.
View More »
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology orders
- View referral status
- Access medical records